-
Product Name
Anti-LILRB3 antibody
- Documents
-
Description
Mouse monoclonal to LILRB3
-
Tested applications
FCM
-
Species reactivity
Human LILRB3
-
Alternative names
CD85A antibody; Lilrb3 antibody; LIR-3 antibody; Gp91 antibody; HL9 antibody; ILT5 antibody; LILRB3 antibody; LIR3 antibody; MGC138403 antibody; Pirb antibody; PIRB antibody; XXbac-BCX105G6.7 antibody
- Immunogen
-
Isotype
Mouse IgG1
-
Preparation
This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human LILRB3 (rh LILRB3; NP_006855.2; Met 1-Glu 443) and conjugated with FITC under optimum conditions, the unreacted FITC was removed.
-
Clonality
Monoclonal
-
Formulation
Aqueous solution containing 0.5% BSA and 0.09% sodium azide
-
Storage instructions
This antibody is stable for 12 months from date of receipt when stored at 2℃-8℃. Protected from prolonged exposure to light. Do not freeze !
Sodium azide is toxic to cells and should be disposed of properly. Flush with large volumes of water during disposal. -
Applications
FCM
-
Validations
LILRB3 Antibody (FITC), Mouse MAb, Flow cytometric analysis
Flow cytometric analysis of Human LILRB3(CD85a) expression on human whole blood monocytes (left panel) and granulocytes (right panel). Cells were stained with FITC conjugated anti-Human LILRB3(CD85a). The histograms were derived from gated events with the forward and side light-scatter characteristics of viable monocytes and granulocytes.
-
Background
Leukocyte immunoglobulin-like receptor subfamily B member 3, also known as Leukocyte immunoglobulin-like receptor 3, Immunoglobulin-like transcript 5, Monocyte inhibitory receptor HL9, CD85 antigen-like family member A, CD85a and LILRB3, is a single-pass type I membrane protein which belongs to the leukocyte receptor cluster (LRC) present on 19q13.4. LILRB3 / CD85a contains four Ig-like C2-type (immunoglobulin-like) domains. LILRB3 / CD85a contains three copies of a cytoplasmic motif that is referred to as the immunoreceptor tyrosine-based inhibitor motif (ITIM). This motif is involved in modulation of cellular responses. The phosphorylated ITIM motif can bind the SH2 domain of several SH2-containing phosphatases. LILRB3 / CD85a is expressed on immune cells where it binds to MHC class I molecules on antigen-presenting cells and transduces a negative signal that inhibits stimulation of an immune response. It is thought to control inflammatory responses and cytotoxicity to help focus the immune response and limit autoreactivity. Multiple transcript variants encoding different isoforms have been found.
-
References
- Huang,J. et al., 2010, J Virol. 84 (18): 9463-71.
- Arm J.P. et al., 1997, J. Immunol. 159:2342-2349.
- Wende H. et al., 2000, Immunogenetics 51:703-713.
- Yu L.-R. et al., 2007,J. Proteome Res. 6:4150-4162.
Related Products / Services
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"